Life Science Investing Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy 02 December
Life Science Investing Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease 21 November
Life Science Investing Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results 06 November
